Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Barclays PLC (BCS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Barclays PLC — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Barclays PLC trades at $27.28 (market cap $91.26B). The key difference: Barclays PLC is far larger — about 2.3× Alnylam Pharmaceuticals, Inc.'s market cap, and Barclays PLC pays a 1.67% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | BCS | |
|---|---|---|
Market Cap | $39.89B | $91.26B |
Sector | Health | Financials |
52-Week High | $491.22 | $28.41 |
52-Week Low | $278.09 | $18.40 |
Enterprise Value | $38.15B | — |
Dividend Yield | — | 1.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Barclays PLC (BCS) trades at $27.48, up 0.88% today, near its 52-week high of $28.43. The stock shows a bullish technical trend with strong moving average signals. Fundamentally, revenue grew to $29.14B in 2025 with a robust net income margin of 24.5%, while the P/E ratio of 11.99 suggests reasonable valuation. Recent earnings beats and positive analyst sentiment support the uptrend.
The outlook remains positive given consistent earnings outperformance and Wall Street's bullish stance, though risks include ongoing legal investigations and volatile cash flow patterns. Investment appeal hinges on sustained profitability and resolution of legal overhangs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Barclays PLC
Barclays is a universal bank headquartered in the United Kingdom. It operates via two principal segments
Read more on BCS →
